A study by Feldheim et al. [33] also evaluated ATF5 immunostaining in a set of samples from WHO grade II low-grade astrocytomas, as well as from normal brain and GBM. The gene discussed is ATF5; the disease is astrocytoma (excluding glioblastoma).